“Vitamin D supplementation and COVID-19 treatment: A systematic review and meta-analysis”

Rawat, Dimple; Roy, Avishek; Maitra, Souvik; Shankar, Vikas; Khanna, Puneet; Baidya, Dalim Kumar

doi:10.1016/j.dsx.2021.102189

Cited by 90 publications

(94 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This could be explained by the fact that a deficiency of a certain vitamin may not necessarily indicate a disease process, rather it might be an outcome. In addition, the administration of vitamins after diagnosis of SARS-CoV-2 infection may not be as effective as a physiological replenished state before the diagnosis [ 62 , 63 ].…”

Section: Discussionmentioning

confidence: 99%

Dietary supplements intake during the second wave of COVID-19 pandemic: A multinational Middle Eastern study

Mukattash

Alkhalidy

Alzu'bi

et al. 2022

European Journal of Integrative Medicine

View full text Add to dashboard Cite

Introduction Despite the controversy about the benefits of dietary supplements in treating or preventing COVID-19, their use has increased worldwide even with the introduction of relevant vaccines. Thus, this study aimed to investigate the perception of Middle Eastern Arab publics of dietary supplements as prophylactic or therapeutic agents against COVID-19, and their consumption during the second wave of COVID-19 pandemic. Methods A validated, pilot tested online survey was distributed through social networking platforms in Lebanon, the Kingdom of Saudi Arabia, Palestine, Jordan, and the United Arab Emirates. Responses underwent various statistical analyses. Results A total of 2,100 responses were included. Around 44% of participants reported changes in their dietary behavior during COVID-19, and 70% believed that healthy habits may prevent the infection. Moreover, 21% believed that dietary supplements surely protect against COVID-19 and 45% thought they aid in treating it. Users of supplements during the second wave of the pandemic counted for 47%, who declared they were influenced by the media, healthcare providers, or close people. The most used supplements included Vitamins C and D and zinc. Only 34% of participants were reading supplement leaflets. The use of supplements was significantly correlated with females and exercisers, as revealed by the odds ratio and logistic regression analysis. Conclusions In line with other areas of the world, the use of dietary supplements in the Middle East against COVID-19 is not evidence-based. Competent health authorities should play their role in spreading sound awareness among the public regarding this issue.

show abstract

Section: Discussionmentioning

confidence: 99%

Dietary supplements intake during the second wave of COVID-19 pandemic: A multinational Middle Eastern study

Mukattash

Alkhalidy

Alzu'bi

et al. 2022

European Journal of Integrative Medicine

View full text Add to dashboard Cite

show abstract

“…Il-6, TNF), interferon, and chemokines ( Greiller and Martineau, 2015 ). A meta-analysis published by Rawat et al, examining the use of vitamin D in patients with COVID-19 demonstrated no significant reduction in mortality, ICU admission, or the need for invasive ventilation in patients receiving vitamin D supplementation ( Rawat et al, 2021 ).…”

Section: Other Agents Tested For Potential Efficacy In Treating Covid-19 Infectionmentioning

confidence: 99%

“… Drug No. patients Outcome Effect Vitamin D ( Rawat et al, 2021 ) 467 Mortality reduction No effect; R = 0.55 (95% CI 0.22 - 1.39), p = 0.21 HCQ ( Amani et al, 2021 ) 6,059 Mortality reduction No effect, RR = 0.7 (95% CI: 0.24 - 1.99) HCQ ( Bartoszko et al, 2021 ) 8,161 Side effects RR = 1.81 (95% CI: 1.36 - 2.42), p < 0.05 HCQ ( Axfors et al, 2021 ) 10,012 Increase of mortality OR = 1.11 (95% CI: 1.02 - 1.20) Convalescent plasma ( Bansal et al, 2021b ) 27,706 Mortality reduction OR 0.76 (95% CI: 0.53–1.08), p = 0.13 Sarilumab ( Lescure et al, 2021b ) 416 Positive effect HR = 1.03 (95% CI 0.75 - 1.40]; p = 0.96 Legend: HCQ – hydroxychloroquine; HR – hazard ratio; OR – odds ratio; RR – risk ratio; 95% Cl – 95 % confidence interval …”

Section: Other Agents Tested For Potential Efficacy In Treating Covid-19 Infectionmentioning

confidence: 99%

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

Drożdżal

Rosik

Lechowicz

et al. 2021

Drug Resistance Updates

211

157

View full text Add to dashboard Cite

The COVID-19 pandemic is one of the greatest threats to human health in the 21 st century with more than 257 million cases and over 5.17 million deaths reported worldwide (as of November 23, 2021. Various agents were initially proclaimed to be effective against SARS-CoV-2, the etiological agent of COVID-19. Hydroxychloroquine, lopinavir/ritonavir, and ribavirin are all examples of therapeutic agents, whose efficacy against COVID-19 was later disproved. Meanwhile, concentrated efforts of researchers and clinicians worldwide have led to the identification of novel therapeutic options to control the disease including PAXLOVID™ (PF-07321332). Although COVID-19 cases are currently treated using a comprehensive approach of anticoagulants, oxygen, and antibiotics, the novel Pfizer agent PAXLOVID™ (PF-07321332), an investigational COVID-19 oral antiviral candidate, significantly reduced hospitalization time and death rates, based on an interim analysis of the phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. The scheduled interim analysis demonstrated an 89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset (primary endpoint). However, there still exists a great need for the development of additional treatments, as the recommended therapeutic options are insufficient in many cases. Thus far, mRNA and vector vaccines appear to be the most effective modalities to control the pandemic. In the current review, we provide an update on the progress that has been made since April 2020 in clinical trials concerning the effectiveness of therapies available to combat COVID-19. We focus on currently recommended therapeutic agents, including steroids, various monoclonal antibodies, remdesivir, baricitinib, anticoagulants and PAXLOVID™ summarizing the latest original studies and meta-analyses. Moreover, we aim to discuss other currently and previously studied agents targeting COVID-19 that either show no or only limited therapeutic activity. The results of recent studies report that hydroxychloroquine and convalescent plasma demonstrate no efficacy against SARS-CoV-2 infection. Lastly, we summarize the studies on various drugs with incoherent or insufficient data concerning their effectiveness, such as amantadine, ivermectin, or niclosamide.

show abstract

“…Based on these and similar studies, it was suggested that vitamin D supplementation of the general population might reduce the viral spread and decrease the disease severity and thereby aid in tackling the SARS-CoV-2 pandemic (1,3,5,6,(10)(11)(12). However, recent meta-analyses found that the evidence to support vitamin D supplementation for the prevention or treatment of COVID-19 was inconclusive (13)(14)(15). In line with this, a randomized, double-blind, placebocontrolled trial found that vitamin D supplementation did not reduce the overall risk of acute respiratory tract infection in general (16).…”

Section: Introductionmentioning

confidence: 99%

Normal T and B Cell Responses Against SARS-CoV-2 in a Family With a Non-Functional Vitamin D Receptor: A Case Report

et al. 2021

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has severely impacted daily life all over the world. Any measures to slow down the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to decrease disease severity are highly requested. Recent studies have reported inverse correlations between plasma levels of vitamin D and susceptibility to SARS-CoV-2 infection and COVID-19 severity. Therefore, it has been proposed to supplement the general population with vitamin D to reduce the impact of COVID-19. However, by studying the course of COVID-19 and the immune response against SARS-CoV-2 in a family with a mutated, non-functional vitamin D receptor, we here demonstrate that vitamin D signaling was dispensable for mounting an efficient adaptive immune response against SARS-CoV-2 in this family. Although these observations might not directly be transferred to the general population, they question a central role of vitamin D in the generation of adaptive immunity against SARS-CoV-2.

show abstract

“Vitamin D supplementation and COVID-19 treatment: A systematic review and meta-analysis”

Cited by 90 publications

References 33 publications

Dietary supplements intake during the second wave of COVID-19 pandemic: A multinational Middle Eastern study

Dietary supplements intake during the second wave of COVID-19 pandemic: A multinational Middle Eastern study

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

Normal T and B Cell Responses Against SARS-CoV-2 in a Family With a Non-Functional Vitamin D Receptor: A Case Report

Contact Info

Product

Resources

About